Stockreport

Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF Operating Expenses : Q4 operating expenses decreased to $8.2 million, down from $8.5 million in Q4 2022. Net Loss : Q4 net loss improved to $4.8 million, or $0.03 per [Read more]